Year |
Citation |
Score |
2019 |
Oberlick EM, Rees MG, Seashore-Ludlow B, Vazquez F, Nelson GM, Dharia NV, Weir BA, Tsherniak A, Ghandi M, Krill-Burger JM, Meyers RM, Wang X, Montgomery P, Root DE, Bieber JM, et al. Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Reports. 28: 2331-2344.e8. PMID 31461650 DOI: 10.1016/J.Celrep.2019.07.021 |
0.3 |
|
2017 |
Ilic N, Birsoy K, Aguirre AJ, Kory N, Pacold ME, Singh S, Moody SE, DeAngelo JD, Spardy NA, Freinkman E, Weir BA, Tsherniak A, Cowley GS, Root DE, Asara JM, et al. PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America. PMID 28396387 DOI: 10.1073/Pnas.1617922114 |
0.356 |
|
2015 |
Gannon HS, Kaplan N, Tsherniak A, Vazquez F, Weir BA, Hahn WC, Meyerson M. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-targeted Therapy. Molecular Cancer Research : McR. PMID 26582713 DOI: 10.1158/1541-7786.Mcr-15-0321 |
0.326 |
|
2012 |
Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. Plos Genetics. 8: e1002772. PMID 22829774 DOI: 10.1371/Journal.Pgen.1002772 |
0.339 |
|
2010 |
Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics. 42: 715-21. PMID 20601955 DOI: 10.1038/Ng.619 |
0.326 |
|
2009 |
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, ... ... Weir BA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462: 108-12. PMID 19847166 DOI: 10.1038/Nature08460 |
0.305 |
|
2008 |
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, ... ... Weir BA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455: 1069-75. PMID 18948947 DOI: 10.1038/Nature07423 |
0.312 |
|
2007 |
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 26: 5023-7. PMID 17311002 DOI: 10.1038/Sj.Onc.1210292 |
0.335 |
|
Show low-probability matches. |